Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Front Biosci (Landmark Ed) ; 28(5): 96, 2023 05 22.
Article in English | MEDLINE | ID: mdl-37258484

ABSTRACT

Silicosis, an occupational lung disease that can be prevented, is still a significant public health concern in many countries, despite its considerably decreased incidence over the years. The latency period for silicosis ranges from a few years to several decades, depending on the duration and intensity of exposure to silica dust. The complex pathogenic mechanisms of the disease are not fully understood, but it is known to be characterized by inflammation, the formation of silicotic nodules, and progressive and irreversible fibrosis. The aim of this paper was to present the current sources of exposure to silica dust and summarize the updates on risk factors (e.g., socioeconomic status, genetic susceptibility) and sex differences, silico-tuberculosis, prognostic markers including 16-kDa Clara cell secretory protein, antifibrotic treatment, and other therapeutic possibilities with promising results. There are no effective treatment options for silicosis, and prevention remains the primary tool to significantly reduce the risk of disease. There are promising new treatments under investigation including antifibrotic, cellular, and immunomodulatory therapies, but further research is needed to demonstrate the efficacy and safety of these therapies in adequately powered clinical trials.


Subject(s)
Silicon Dioxide , Silicosis , Female , Humans , Male , Silicon Dioxide/adverse effects , Silicosis/therapy , Silicosis/epidemiology , Silicosis/etiology , Fibrosis , Inflammation/chemically induced , Dust
2.
Article in English | MEDLINE | ID: mdl-36429481

ABSTRACT

Asbestos use started to be gradually banned in Europe from 1991 onwards, and there are currently strict occupational exposure limits for asbestos. However, malignant mesothelioma has a long latency time (in some cases up to 50-60 years), so the risks related to asbestos exposure should not be forgotten. Considering the increased risk of lung cancer following the inhalation of asbestos fibers, lifetime health monitoring should be considered in people occupationally exposed to asbestos, with an emphasis on the respiratory system. An assessment of their occupational history should be performed rigorously, especially in the areas with a history of asbestos production/use, as this is a key element for an early diagnosis and appropriate treatment. This case report presents a near-missed case of occupational pleural malignant mesothelioma. The latency time between the first asbestos exposure and the diagnosis of occupational pleural malignant mesothelioma was 49 years. The accurate diagnosis was made two years after the first symptoms appeared.


Subject(s)
Asbestos , Mesothelioma, Malignant , Mesothelioma , Occupational Exposure , Pleural Neoplasms , Humans , Mesothelioma/chemically induced , Mesothelioma/diagnosis , Mesothelioma/therapy , Pleural Neoplasms/diagnosis , Pleural Neoplasms/therapy , Pleural Neoplasms/complications , Asbestos/adverse effects , Occupational Exposure/adverse effects
3.
Am J Ther ; 27(3): e249-e269, 2020.
Article in English | MEDLINE | ID: mdl-32118591

ABSTRACT

BACKGROUND: The systematic reviews and meta-analyses performed until now did not provide the adequate picture of actual knowledge in the field of neuropsychiatric symptoms treatment using psychotropic cannabinoids in patients with Alzheimer disease (AD). THE STUDY QUESTION: Which is the level of evidence, from quantitative and qualitative point of view, concerning the efficacy and safety of the treatment with psychotropic cannabinoids of neuropsychiatric symptoms in AD? STUDY DESIGN: PubMed, EMBASE, Cochrane Database of Systematic Reviews, Google Scholar Data, and Clinicaltrials.gov were searched for randomized clinical trials with cannabinoids in Alzheimer dementia agitation and aggression. MEASURES AND OUTCOMES: The rationale, the objectives, and the methods used for searching the trials have been established according to PRISMA Criteria 2009. RESULTS: The total number of patients in the 9 publications evaluated in this study, which included data from 6 clinical trials, was 422 patients-treatments, where treatment was a psychoactive cannabinoid or placebo, some of them obtained by multiplying selected patients with the number of cannabinoid treatments in the crossover studies. There are multiple sources of bias in the analyzed studies; 2 elements have prevented conclusive results. One element was polypragmazia, a major role being played by the use of psychotropic drugs other than cannabinoids, in an effort to reduce agitation and aggressive behavior. The second one was the large number of concomitant symptoms, for example, pain (commonly causing anxiety and agitation). CONCLUSIONS: No clear conclusion can be drawn on the effectiveness of psychoactive cannabinoids in the treatment of psychiatric manifestations, in particular agitation and aggression, in AD. In the future, large randomized controlled trial with adequate designs, without crossover and for longer duration, adapted to cannabinoid pharmacokinetics, is required to establish the real efficacy and safety of these drugs in aggressive and/or agitated patients with AD.


Subject(s)
Aggression/drug effects , Alzheimer Disease/complications , Anxiety/drug therapy , Cannabinoids/administration & dosage , Psychomotor Agitation/drug therapy , Psychotropic Drugs/administration & dosage , Alzheimer Disease/drug therapy , Alzheimer Disease/psychology , Anxiety/etiology , Anxiety/psychology , Cannabinoids/adverse effects , Cannabinoids/pharmacokinetics , Humans , Psychomotor Agitation/etiology , Psychomotor Agitation/psychology , Psychotropic Drugs/adverse effects , Psychotropic Drugs/pharmacokinetics , Randomized Controlled Trials as Topic , Treatment Outcome
4.
Rom J Ophthalmol ; 61(1): 32-38, 2017.
Article in English | MEDLINE | ID: mdl-29450368

ABSTRACT

Aim: The aim of this paper was to describe the possible implications of topical (ocular) administration of Metamizole on vascular reactivity of the iris in Wistar rats. No other study regarding its topical use was found. Methods: Male adult Wistar rats were anaesthetized with Ketamine 100 mg /kg body weight - injected intraperitoneally - while maintaining spontaneous respiration and the blink reflex. After selecting the area of interest (long posterior ciliary artery - LPCA), manual adjustments of the image magnitude, clarity, and brightness were made, and the experiment began. The image recording lasted 10 minutes. Results: Metamizole induced a slight vasoconstriction that started with the initial moment for all the doses used. After the topical administration of Metamizole, we did not observe an increase of the vascular diameter of LPCA in a dose dependent manner. The saline solution used as a negative control did not modify the vessel diameter. Conclusions: Metamizole (dipyrone) is a non-opioid drug, which is commonly used in human and veterinary medicine. It is the most popular first-line analgesic in various populations. In some cases, this agent is still incorrectly classified as a non-steroidal anti-inflammatory drug. The high analgesic efficacy of metamizole, as well as its spasmolytic effect, makes it a very important pharmaceutical agent that could be used in the therapy of various eye disorders in humans and in animals. Abbreviations: COX = Cyclooxygenase; LPCA = Long Posterior Ciliary Artery; PRP = panretinal photocoagulation; PDR = proliferative diabetic retinopathy; Sec = second(s); VSPR = very severe non proliferative diabetic retinopathy.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Ciliary Arteries/physiology , Dipyrone/administration & dosage , Iris/blood supply , Vasoconstriction/drug effects , Administration, Ophthalmic , Animals , Dose-Response Relationship, Drug , Male , Ophthalmic Solutions , Rats , Rats, Wistar
5.
Rom J Morphol Embryol ; 50(2): 169-79, 2009.
Article in English | MEDLINE | ID: mdl-19434307

ABSTRACT

Different classes of receptors mediate norepinephrine and epinephrine effects, one of the most recently discovered being the beta 3 adrenergic ones. The paper has proposed itself to present the history of the discovery of beta 3 adrenergic receptors, different techniques for their identification, their structure, localization, genetic data and also the mechanism of regulation of their functions. It also contains an exhaustive approach regarding the histological localization and functions of beta 3 adrenergic receptors in different apparatus and systems, making evident their effect on glucidic, lipidic and energetic metabolism. The substances that influence beta 3 adrenergic receptors activities, especially the agonists, have been studied regarding their practical applications in the treatment of diabetes mellitus and of the disturbances of lipid metabolism.


Subject(s)
Receptors, Adrenergic, beta-3/physiology , Animals , Energy Metabolism , Epinephrine/metabolism , Glycosylation , Humans , Lipid Metabolism , Norepinephrine/metabolism , Organ Specificity , Protein Conformation , Receptors, Adrenergic, beta-3/chemistry , Receptors, Adrenergic, beta-3/genetics
6.
Oftalmologia ; 51(4): 126-33, 2007.
Article in Romanian | MEDLINE | ID: mdl-18543689

ABSTRACT

INTRODUCTION: Serotonin presents specific receptors of many types and subtypes. The aim of this study was to analyze the differences in reactivity between the vessels (arteries and veins) of the iris and conjunctiva. The vascular diameter was measured using a noninvasive technique after intraocular administration of different doses of serotonin. MATERIAL AND METHODS: The tests were performed on rats, divided in control and study groups. The modifications of studied vessels' diameters before and after topical administration of the solutions were evaluated by measuring these diameters at fixed time intervals of 30 seconds, for 6 minutes. Differentiation between arteries and veins was made using topical administration of felodipine after the testing 6 minutes interval The statistical significance of differences between the values obtained in each interval of 30 seconds and the control values at the initial moment was evaluated using t-test, the "paired" variant. RESULTS: There were obtained differences in reactivity between iris and conjunctival vessels and between iris arteries and veins for the different concentrations of tested serotonin solutions. CONCLUSIONS: Iris and conjunctival vessels contain serotonin receptors with different types and densities, whose activation produced vasoconstriction in both territories, but with different evolution and intensity. Differences in reactivity were found between iris arteries and veins, probably due to a different density of receptors between those two territories. The different vascular response might be a protective mechanism against dissemination of conjunctival infections.


Subject(s)
Arteries/drug effects , Conjunctiva/blood supply , Conjunctiva/drug effects , Iris/blood supply , Iris/drug effects , Serotonin Agents/pharmacology , Serotonin/metabolism , Veins/drug effects , Animals , Ciliary Arteries/drug effects , Disease Models, Animal , Felodipine/pharmacology , Male , Rats , Rats, Wistar , Receptors, Serotonin/drug effects , Serotonin/pharmacology , Vasodilator Agents/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...